Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives

Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives

From a complete literature review, we were able to present in this paper what is most current in the treatment with immunotherapy for advanced non-small cell lung cancer (NSCLC). Especially the use of immunotherapy, particularly inhibitors of PD-1 (programmed cell death protein 1), PDL-1 (programmed...

Full description

Bibliographic Details
Main Authors: Ramon Andrade Bezerra De Mello, Rafael Voscaboinik, João Vittor Pires Luciano, Rafaela Vilela Cremonese, Giovanna Araujo Amaral, Pedro Castelo-Branco, Georgios Antoniou
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
immunotherapy
advanced lung cancer
durvalumab
pembrolizumab
atezolizumab
ipilimumab
Online Access:https://www.mdpi.com/2072-6694/14/1/122

Internet

https://www.mdpi.com/2072-6694/14/1/122

Similar Items